DUBLIN – Shares in Polyphor AG gained as much as 12% during early trading Aug. 31 on news of a deal in China for its lead drug, balixafortide, which is currently undergoing a phase III trial in HER2-negative locally recurrent or metastatic breast cancer.
Generex Biotechnology Corp.’s wholly owned subsidiary Nugenerex Health partnered with Worldwide Digitech (WWDT) LLC to create a 50/50 joint venture, Nugenhealth LLC. The new company will draw on WWDT’s software to develop an end-to-end software-as-a-service (SaaS) solution for chronic care management using remote patient monitoring.
TORONTO – After four years of relying on Vivametrica Inc. to successfully boost the health and wellness of its clients’ employees, Sprout Wellness Solutions Inc. has taken the next logical step by acquiring the Calgary-based health analytics company.
LONDON – Ion Beam Applications SA (IBA) has taken a giant step into China, sealing a €100 million-plus (US$118.2 million) licensing deal with a local company to manufacture, install and maintain its proton beam cancer therapy systems.
Hologic Inc., which focuses on women's health, reported Aug. 25 that it was acquiring Acessa Health Inc., a company that has developed a minimally invasive treatment for fibroids. It is offering about $80 million in cash plus contingent payments based on future revenue growth.
HONG KONG – Last week was a busy one for Harbour Biomed Therapeutics Ltd., seeing the company sign a COVID-19 research collaboration with several Dutch institutions as well as lodge an application to list on the Hong Kong Stock Exchange.
HONG KONG – Hua Medicine Ltd. has signed a commercialization and partnership deal with Bayer AG for a new diabetes treatment in China. Hua’s dorzagliatin, a first-in-class dual-acting glucokinase activator, is designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in patients with type 2 diabetes (T2D).
Innovent Biologics Inc., of Suzhou, has out-licensed ex-China rights for its PD-1 drug Tyvyt (sintilimab) to Eli Lilly and Co. in an expanded license deal. The Chinese firm will receive $200 million upfront in the deal, the value of which could approach up to $1.03 billion. Innovent’s CEO Michael Yu called this “the first solid step in getting Innovent's innovative portfolio into the global market.” With the ex-China rights of Tyvyt, Lilly plans to seek approval for the PD-1 drug in the U.S. and other markets.
Moving to build out its central nervous system (CNS) portfolio with an eye to what Acadia Pharmaceuticals Inc. CEO Steve Davis called an "urgent need for new approaches to treat pain without causing addiction," the company is acquiring privately-held Cersci Therapeutics Inc. for $52.5 million, primarily in stock.
RSS
